[go: up one dir, main page]

WO2019002933A1 - Composition de granulés vétérinaires contenant un extrait de chanvre - Google Patents

Composition de granulés vétérinaires contenant un extrait de chanvre Download PDF

Info

Publication number
WO2019002933A1
WO2019002933A1 PCT/IB2018/000707 IB2018000707W WO2019002933A1 WO 2019002933 A1 WO2019002933 A1 WO 2019002933A1 IB 2018000707 W IB2018000707 W IB 2018000707W WO 2019002933 A1 WO2019002933 A1 WO 2019002933A1
Authority
WO
WIPO (PCT)
Prior art keywords
dietary supplement
hemp
veterinary composition
cannabinoids
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/000707
Other languages
English (en)
Inventor
Miriam HALPERIN WERNLI
Jorge WERNLI
Gian Batista TREPP
Silvia Huber
Franco MADEA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creso Pharma Switzerland GmbH
Original Assignee
Creso Pharma Switzerland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creso Pharma Switzerland GmbH filed Critical Creso Pharma Switzerland GmbH
Priority to MX2019015673A priority Critical patent/MX2019015673A/es
Priority to EP18746743.6A priority patent/EP3645119A1/fr
Priority to BR112019026635-6A priority patent/BR112019026635A2/pt
Publication of WO2019002933A1 publication Critical patent/WO2019002933A1/fr
Anticipated expiration legal-status Critical
Priority to CONC2020/0000111A priority patent/CO2020000111A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the invention pertains to veterinary compositions or dietary or feed supplements for use in the prevention or the treatment of behavioral, respectively age-related disorders or troubles in mammals, or for supporting or strengthening the immune system, the behavioral balance of mammals and for supporting the natural inflammatory response of mammals, in particular of companion animals.
  • THC toxicity can be serious and prevent the pet from standing and eating , so overdosage can be counterproductive if not dangerous.
  • compositions making use of hemp or cannabis oils or extracts used as the source of cannabinoids wherein the amount of active substances is easier to control.
  • Such compositions are frequently provided in their liquid, in particular oily form or as capsules which, however, necessitates a very cautious administration.
  • Oils or capsules do not dissolve in the pet mouth and consequently are furthermore subject to significant liver first-pass metabolism as the oral bioavailability of cannabinoids is below In certain cases, an adequate mixing to the pet diet is also of concern, especially when off flavors are too intense and then cause rejection of the diet provided to the pet.
  • composition according to the invention consist in a veterinary composition or dietary supplement or complementary feed which is in the form of water soluble polysaccharide-based granules comprising as the source of cannabinoids as a standardized oil or a standardized extract of hemp (Cannabis sativa L.) essentially devoid of psychotropic substances.
  • mammals define here companion animals like dogs, cats, horses, donkeys and mules and camels or zoo animals where behavioral disorders like anxiety, stress or seizures are frequently of concern.
  • granules defines here edible particles in their granulated form, e.g. such as spherical or similar particles consisting essentially of a water soluble biodegradable matrix containing the selected active substances, wherein the cannabinoids providing from hemp or cannabis extract are dispersed inside or sprayed or coated on the surface.
  • these granules can further comprise additives like stabilizers, binding or disintegrating agents or even flavors.
  • the granules of the invention can be prepared according to the techniques conventional in the art such as extrusion, nebulization or fluid-bed granulation.
  • polysaccharides defines substances commonly used in veterinary or human medicine as carriers and more particularly water-soluble polysaccharides selected among starch, soluble starch, microcrystalline cellulose, dextrin, dextrose, sucrose, isomaltose, oligosaccharides such as fructo-oligosaccharides (FOS) or gluco-oligosaccharides (GOS), mixtures of same and any other water-soluble representatives of this class of compounds. This enumeration, however, is not limitative.
  • the term "essentially devoid of” defines here cannabis or hemp (Cannabis sativa L.) oils or extracts wherein the content of psychotropic substances, namely THC is significantly below the applicable regulatory provisions according to EFSA and EU regulatory bodies
  • standardized oil and "standardized extract” apply to compositions of matter that are either already commercially available or manufactured on request by dedicated companies that are mastering current extraction, e.g. solvent or C02 extraction, and purification techniques and that can deliver oils or extracts with a precisely defined and characterized content in active substances, cannabinoids in the instant case.
  • Standardized hemp (Cannabis sativa L.) extracts used according to the invention present furthermore a high content in non-psychotropic cannabinoids and in particular CBD, namely up to ca. 25 to 50 or even 80 % CBD and with THC less than 0.05 % (weight).
  • An example of a preferred standardized hemp extract comprises 23.6 % CBD, 0.25 % of a mix of CBDV, CBDA & CBG and less than 0.05 % THC (weight).
  • the selected hemp extract is defined as "full spectrum” extract, meaning that it contains a blend of other cannabinoids, terpenes, flavonoids and phytonutrients that boost its bioavailability.
  • the granule composition according to the invention has been conceived to be delivered through a delivery system which maximizes the absorption and the bioavailability to optimize the benefits of the hemp oils extract, in particular the cannabinoids contained therein, essentially CBD and any additional active ingredients.
  • the active ingredients are delivered through granules, which are highly soluble in saliva of the mouth and in water. While oils or capsules do not dissolve in saliva or water and have to go through the gastro-intestinal tract, the active ingredients, namely the cannabinoids, are diffused directly into the blood vessels in the mouth through buccal diffusion.
  • the granule composition according to the invention absorbs straight into the pet's blood through the mucosal membrane in the mouth, allowing the hemp components, i.e. the cannabinoids, mainly CBD here, to bypass the gastrointestinal system and the first pass liver metabolism.
  • the effect is likely as high as 30 % versus 4 to 6 % of that observed when cannabinoids are administered by means of oils.
  • buccal absorption provides a more precise dosing.
  • Veterinary compositions or dietary supplements according to the invention are conveniently used by simple addition or mixing with the regular diet of the selected mammal, e.g. the selected companion animal (pet).
  • the administration follows usually the same feeding pattern as that applied for healthy pets, e.g. once or twice a day. Although this way of administration is preferred, pouring directly granules according to the invention into the pet's mouth is also accepted and even common practice.
  • the dosage of CBD i.e. the main active cannabinoid
  • the dosage of CBD extends conveniently from ca. 0.2 to 10, preferably from 0.2 to 5 mg per day per kg body weight.
  • the prevention of said troubles or disorders requires low 0.2 to 0.5 mg CBD per day per kg body weight.
  • the advice is to start low and increase slowly. Due to the lack of THC negative side effects or even drug addiction are definitely avoided.
  • Severe troubles may require significantly higher dosages over a shortened period, e.g. ca. 10 to 25 mg CBD per day per kg body weight or even more. But even at these doses no negative side effects are predicted as well as any addiction.
  • the veterinary composition or dietary supplement according to the invention can be provided in the form of unit doses each corresponding to one serving as follows: for dogs, sachets, pouches or bags or capsules containing 5 g of granules comprising 10 mg of the hemp (Cannabis sativa L.) extract mentioned here above or, expressed differently 2.0 to 3.0 mg CBD;
  • dogs weighing from 5 to 20 kg are conveniently treated by means of one portion of 5 g granules per day whereas dogs with body weight over that 20 kg are conveniently treated with 3 portions of 5 g per day or even more if ever necessary.
  • sachets containing granules providing up to 8 mg CBD par dose can be used within that frame.
  • horses weighing less than 500 kg are usually provided with one 16 g portion of granules per day which is most frequently administered directly into the mouth, whereas horses weighing more than 500 kg are usually provided with two 16 g doses of granules per day or even more if ever necessary.
  • Camels or zoo animals can be subject to similar dosages as long as the above ratio CBD per day per kg body weight is duly monitored.
  • sucrose 41 % weight
  • dextrose D-glucose monohydrate 58 %
  • glucose syrup 1.4 % weight
  • Micronutrients like Vitamin B6, Niacin and zinc acetate dihydrate can be added to the above formulation if ever desired; the latter can further comprise a stabilizer like gum Arabic or similar. Portions of 5 g granules were then packed individually to afford dose units providing each ca. 10.5 mg hemp extract** corresponding to ca. 2.5 mg CBD per 5 g portion.
  • Portions of 16 granules each manufactured according to the method of Example 1 have been prepared in such a way to comprise 360 to 370 mg of the above hemp extract** or, expressed differently ca. 80 mg CBD per 16 portions.
  • the latter are designed for large mammals like horses, camel and zoo animals.
  • CBD 0.25 % weight (CBDV + CBDA + CBG) and less that 0.05 % weight THC.
  • a sugar-free granule composition was prepared according to Example 1 when substituting the 41 % weight of sucrose by 20 % weight of GOS/FOS and the necessary increase of weight % of dextrose to balance.
  • Such a granule formulation has the advantage to be less caloric and consequently better suited to dogs suffering from age related disorders or diseases like diabetes.
  • This granule formulation is also better suited for treating chronic pain over an extended period.
  • the proportions of dextrose can vary from 30 to 90 % of weight without affecting substantially the delivery of the cannabinoids provided by the hemp extract.
  • sucrose the proportions of which can vary from 10 to 70 % weight whereas those of GOS/FOS are kept between 10 and 20 % weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

Cette invention concerne des compositions vétérinaires ou des compléments diététiques ou alimentaires utiles dans la prévention ou le traitement des troubles du comportement, respectivement liés à l'âge, et de la douleur chez les mammifères. Ils sont également destinés à soutenir ou à renforcer le système immunitaire, le bilan comportemental des mammifères et à soutenir la réponse inflammatoire naturelle. Ces compositions ou compléments se présentent sous la forme de granulés hydrosolubles à base de polysaccharides qui contiennent à titre de source de cannabinoïdes une huile normalisée ou un extrait de chanvre (Cannabis sativa L.) sensiblement dépourvu de substances psychotropes.
PCT/IB2018/000707 2017-06-30 2018-06-25 Composition de granulés vétérinaires contenant un extrait de chanvre Ceased WO2019002933A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2019015673A MX2019015673A (es) 2017-06-30 2018-06-25 Composicion de granulos veterinarios que contiene extracto de ca?amo.
EP18746743.6A EP3645119A1 (fr) 2017-06-30 2018-06-25 Composition de granulés vétérinaires contenant un extrait de chanvre
BR112019026635-6A BR112019026635A2 (pt) 2017-06-30 2018-06-25 composição veterinária ou suplemento de dieta
CONC2020/0000111A CO2020000111A2 (es) 2017-06-30 2020-01-07 Composición de gránulos veterinarios que contiene extracto de cáñamo

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527463P 2017-06-30 2017-06-30
US62/527,463 2017-06-30

Publications (1)

Publication Number Publication Date
WO2019002933A1 true WO2019002933A1 (fr) 2019-01-03

Family

ID=63042061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/000707 Ceased WO2019002933A1 (fr) 2017-06-30 2018-06-25 Composition de granulés vétérinaires contenant un extrait de chanvre

Country Status (5)

Country Link
EP (1) EP3645119A1 (fr)
BR (1) BR112019026635A2 (fr)
CO (1) CO2020000111A2 (fr)
MX (1) MX2019015673A (fr)
WO (1) WO2019002933A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020010454A1 (fr) * 2018-07-10 2020-01-16 Beleave Inc. Formulation de composés cannabinoïdes
CN111978417A (zh) * 2019-09-06 2020-11-24 云南汉盟制药有限公司 一种大麻多糖的提取方法及其产品和应用
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039843A2 (fr) * 2007-09-26 2009-04-02 Letzel Heinz Extrait de plantes de cannabis à faible thc pour le traitement de maladies
WO2016094810A2 (fr) * 2014-12-12 2016-06-16 Ojai Energetics Pbc Compositions de cannabinoïdes microencapsulées

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039843A2 (fr) * 2007-09-26 2009-04-02 Letzel Heinz Extrait de plantes de cannabis à faible thc pour le traitement de maladies
US20100216872A1 (en) * 2007-09-26 2010-08-26 Heinz Letzel Plant extract from low-thc cannabis for the treatment of disease
WO2016094810A2 (fr) * 2014-12-12 2016-06-16 Ojai Energetics Pbc Compositions de cannabinoïdes microencapsulées

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084770B2 (en) 2016-12-07 2021-08-10 Treehouse Biotech, Inc. Cannabis extracts
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
WO2020010454A1 (fr) * 2018-07-10 2020-01-16 Beleave Inc. Formulation de composés cannabinoïdes
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
CN111978417A (zh) * 2019-09-06 2020-11-24 云南汉盟制药有限公司 一种大麻多糖的提取方法及其产品和应用
CN111978417B (zh) * 2019-09-06 2021-08-06 云南汉盟制药有限公司 一种大麻多糖的提取方法及其产品和应用

Also Published As

Publication number Publication date
MX2019015673A (es) 2020-02-26
EP3645119A1 (fr) 2020-05-06
CO2020000111A2 (es) 2020-01-17
BR112019026635A2 (pt) 2020-06-30

Similar Documents

Publication Publication Date Title
WO2019002933A1 (fr) Composition de granulés vétérinaires contenant un extrait de chanvre
US20210008027A1 (en) Oral compositions delivering therapeutically effective amounts of cannabinoids
US10493032B2 (en) Nutritional and medicinal oral composition for veterinary use
KR20180103836A (ko) 포도 및 블루베리 혼합물을 포함하는 특수한 영양용 또는 치료용 제제
US20230149318A1 (en) Combinations of nanoparticle-encapsulated cargo entities and methods for making and using same
US20160279058A1 (en) Protein-based gel delivery system
CA3010861A1 (fr) Administration de cannabinoides par l'intermediaire d'aliments
US20230056488A1 (en) Composition, article and method for affecting a mammal
EP2135512B1 (fr) Composition à base d'acide malique, d'acide de café, de flavane-3-ol et d'un anthocyane et leur utilisation dans des produits alimentaires et en médecine
CN104394864B (zh) 含有芝麻素类、γ-谷维素和米胚芽油的组合物
CN101827588B (zh) 用于认知功能的含有百里香酚和/或对-伞花烃的新颖的药物组合物或植物提取物
CA3152428A1 (fr) Produit cannabinoide pour ameliorer la sante musculo-squelettique
CA2983091A1 (fr) Composition pour faciliter la production du facteur neurotrophique derive du cerveau
AU2009333239B2 (en) Antioxidant-containing food composition for use in inhibiting histamine pathways in companion animals
US11752185B2 (en) Powderized cannabis oil
EP3206663B1 (fr) Capsules abaissant le taux de cholestérol
AU2006347121B2 (en) Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia
CN101505774B (zh) 含有来自金合欢属树皮的物质的搔痒预防和/或治疗用组合物
CN121313723A (zh) 一种具有降血糖功效的天然山茶油
TW202434209A (zh) 含有槲皮素或其配糖體的抑制或改善腎功能降低用之組成物
WO2024232981A1 (fr) Compositions comprenant des composés végétaux complexés avec un métal et leurs utilisations
BE1019408A5 (nl) Gebruik van 1,25-dihydroxyvitamine d3 glycoside bij melkgevende dieren.
WO2021189109A1 (fr) Formulation d'amélioration de la quercétine
TW202510892A (zh) 用於預防、改善及／或治療肌肉疾病或肌肉失調之組合
KR20210033433A (ko) 반려동물용 현탁액 조성물 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18746743

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019026635

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: NC2020/0000111

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: NC2020/0000111

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2018746743

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018746743

Country of ref document: EP

Effective date: 20200130

ENP Entry into the national phase

Ref document number: 112019026635

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20191213